Exact Mass: 351.1345

Exact Mass Matches: 351.1345

Found 89 metabolites which its exact mass value is equals to given mass value 351.1345, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Lomefloxacin

(+-)-1-Ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid

C17H19F2N3O3 (351.1394)


Lomefloxacin is only found in individuals that have used or taken this drug. It is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections. It is also used to prevent urinary tract infections prior to surgery.Lomefloxacin is a bactericidal fluoroquinolone agent with activity against a wide range of gram-negative and gram-positive organisms. The bactericidal action of lomefloxacin results from interference with the activity of the bacterial enzymes DNA gyrase and topoisomerase IV, which are needed for the transcription and replication of bacterial DNA. DNA gyrase appears to be the primary quinolone target for gram-negative bacteria. Topoisomerase IV appears to be the preferential target in gram-positive organisms. Interference with these two topoisomerases results in strand breakage of the bacterial chromosome, supercoiling, and resealing. As a result DNA replication and transcription is inhibited. J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01M - Quinolone antibacterials > J01MA - Fluoroquinolones D000970 - Antineoplastic Agents > D059003 - Topoisomerase Inhibitors > D059005 - Topoisomerase II Inhibitors S - Sensory organs > S01 - Ophthalmologicals > S01A - Antiinfectives > S01AE - Fluoroquinolones D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D024841 - Fluoroquinolones C254 - Anti-Infective Agent > C258 - Antibiotic > C795 - Quinolone Antibiotic D004791 - Enzyme Inhibitors

   

Tazarotene

ethyl 6-[2-(4,4-dimethyl-3,4-dihydro-2H-1-benzothiopyran-6-yl)ethynyl]pyridine-3-carboxylate

C21H21NO2S (351.1293)


Tazarotene is only found in individuals that have used or taken this drug. It is a prescription topical retinoid sold as a cream or gel. This medication is approved for treatment of psoriasis, acne, and sun damaged skin (photodamage). [Wikipedia]Although the exact mechanism of tazarotene action is not known, studies have shown that the active form of the drug (tazarotenic acid) binds to all three members of the retinoic acid receptor (RAR) family: RARa, RARb, and RARg, but shows relative selectivity for RARb, and RARg and may modify gene expression. It also has affinity for RXR receptors. C274 - Antineoplastic Agent > C2122 - Cell Differentiating Agent > C1934 - Differentiation Inducer C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C804 - Retinoic Acid Agent D - Dermatologicals > D05 - Antipsoriatics > D05A - Antipsoriatics for topical use C308 - Immunotherapeutic Agent > C129820 - Antineoplastic Immunomodulating Agent D003879 - Dermatologic Agents > D007641 - Keratolytic Agents D009676 - Noxae > D013723 - Teratogens Same as: D01132

   
   

Adinazolam

({12-chloro-9-phenyl-2,4,5,8-tetraazatricyclo[8.4.0.0²,⁶]tetradeca-1(10),3,5,8,11,13-hexaen-3-yl}methyl)dimethylamine

C19H18ClN5 (351.1251)


Adinazolam is only found in individuals that have used or taken this drug. It is a benzodiazepine derivative. It possesses anxiolytic, anticonvulsant, sedative, and antidepressant properties. Adinazolam was developed by Dr. Jackson B. Hester, who was seeking to enhance the antidepressant properties of alprazolam, which he also developed.Adinazolam binds to peripheral-type benzodiazepine receptors which interact allosterically with GABA receptors. This potentiates the effects of the inhibitory neurotransmitter GABA, increasing the inhibition of the ascending reticular activating system and blocking the cortical and limbic arousal that occurs following stimulation of the reticular pathways. D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents N - Nervous system > N05 - Psycholeptics > N05B - Anxiolytics > N05BA - Benzodiazepine derivatives C78272 - Agent Affecting Nervous System > C29756 - Sedative and Hypnotic > C1012 - Benzodiazepine C78272 - Agent Affecting Nervous System > C28197 - Antianxiety Agent

   

2-(3,4,5-Trimethoxybenzoyl)-4,4-diethyl-3,5-isoxazolidinedione

4,4-diethyl-2-(3,4,5-trimethoxybenzoyl)-1,2-oxazolidine-3,5-dione

C17H21NO7 (351.1318)


   

Epicillin

6-[2-amino-2-(cyclohexa-1,4-dien-1-yl)acetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid

C16H21N3O4S (351.1253)


   

Maybridge2_000779

Maybridge2_000779

C22H19F2NO (351.1435)


   

3-methylcarboxymethyl-indole-1-N-beta-D-glucopyranoside

3-methylcarboxymethyl-indole-1-N-beta-D-glucopyranoside

C17H21NO7 (351.1318)


   

methyl 1-(1-b-Glucopyranosyl)-1H-indole-3-acetate

methyl 1-(1-b-Glucopyranosyl)-1H-indole-3-acetate

C17H21NO7 (351.1318)


   

4,9-dihydroxy-2-nonenoic mercapturic acid

4,9-dihydroxy-2-nonenoic mercapturic acid

C14H25NO7S (351.1352)


   
   
   
   
   
   
   
   
   
   
   
   
   
   
   

(E)-1-(L-cysteinylglycin-S-yl)-N-hydroxy-omega-(methylsulfanyl)heptan-1-imine

(E)-1-(L-cysteinylglycin-S-yl)-N-hydroxy-omega-(methylsulfanyl)heptan-1-imine

C13H25N3O4S2 (351.1286)


   

Tazarotene

Tazarotene (Avage)

C21H21NO2S (351.1293)


C274 - Antineoplastic Agent > C2122 - Cell Differentiating Agent > C1934 - Differentiation Inducer C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C804 - Retinoic Acid Agent D - Dermatologicals > D05 - Antipsoriatics > D05A - Antipsoriatics for topical use C308 - Immunotherapeutic Agent > C129820 - Antineoplastic Immunomodulating Agent D003879 - Dermatologic Agents > D007641 - Keratolytic Agents D009676 - Noxae > D013723 - Teratogens Same as: D01132

   
   
   
   
   
   
   
   
   

Adinazolamum

({12-chloro-9-phenyl-2,4,5,8-tetraazatricyclo[8.4.0.0^{2,6}]tetradeca-1(10),3,5,8,11,13-hexaen-3-yl}methyl)dimethylamine

C19H18ClN5 (351.1251)


D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents N - Nervous system > N05 - Psycholeptics > N05B - Anxiolytics > N05BA - Benzodiazepine derivatives C78272 - Agent Affecting Nervous System > C29756 - Sedative and Hypnotic > C1012 - Benzodiazepine C78272 - Agent Affecting Nervous System > C28197 - Antianxiety Agent

   

(Rac)-Rotigotine hydrochloride

(Rac)-Rotigotine hydrochloride

C19H26ClNOS (351.1424)


(Rac)-Rotigotine hydrochloride is a racemate of Rotigotine. Rotigotine is a full agonist of?dopamine receptor, a partial agonist of the?5-HT1A receptor, and an antagonist of the?α2B-adrenergic receptor, with?Kis of 0.71?nM, 4-15?nM, and 83?nM for the dopamine D3 receptor and D2, D5, D4 receptors, and dopamine D1 receptor.

   

5,6,7,8-Tetrahydro-6-[propyl[2-(3-thienyl)ethyl]amino]-1-naphthalenol hydrochloride

5,6,7,8-Tetrahydro-6-[propyl[2-(3-thienyl)ethyl]amino]-1-naphthalenol hydrochloride

C19H26ClNOS (351.1424)


   

4-(2-carboxy-6-nitro-phenyl)-piperazine-1-carboxylic acid tertier-butyl ester

4-(2-carboxy-6-nitro-phenyl)-piperazine-1-carboxylic acid tertier-butyl ester

C16H21N3O6 (351.143)


   

4-(BOC-PIPERAZIN-1-YL)-3-NITROBENZOIC A&

4-(BOC-PIPERAZIN-1-YL)-3-NITROBENZOIC A&

C16H21N3O6 (351.143)


   

Glimepiride sulfonamide

Glimepiride sulfonamide

C16H21N3O4S (351.1253)


   

Ethyl 5-hydroxy-8-isopentyl-2-(methylthio)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carboxylate

Ethyl 5-hydroxy-8-isopentyl-2-(methylthio)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carboxylate

C16H21N3O4S (351.1253)


   

rotigotine hydrochloride

rotigotine hydrochloride

C19H26ClNOS (351.1424)


Rotigotine Hydrochloride (N-0923 Hydrochloride) is a full agonist of dopamine receptor, a partial agonist of the 5-HT1A receptor, and an antagonist of the α2B-adrenergic receptor, with Ki of 0.71?nM, 4-15?nM, and 83?nM for the dopamine D3 receptor and D2, D5, D4 receptors, and dopamine D1 receptor.

   

epicillin

epicillin

C16H21N3O4S (351.1253)


J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01C - Beta-lactam antibacterials, penicillins > J01CA - Penicillins with extended spectrum A penicillin in which the substituent at position 6 of the penam ring is a (2R)-2-amino-2-(cyclohexa-1,4-dien-1-yl)acetamido group. D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D010406 - Penicillins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams C254 - Anti-Infective Agent > C258 - Antibiotic > C260 - Beta-Lactam Antibiotic

   

PIK-90

N-(7,8-dimethoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)nicotinamide

C18H17N5O3 (351.1331)


   

1-N-BOC-4-(3-CARBOXY-4-NITROPHENYL)PIPERAZINE

1-N-BOC-4-(3-CARBOXY-4-NITROPHENYL)PIPERAZINE

C16H21N3O6 (351.143)


   

H-Glu-Gly-Phe-OH

H-Glu-Gly-Phe-OH

C16H21N3O6 (351.143)


   

2,4,6-Triphenylnitrobenzene

2,4,6-Triphenylnitrobenzene

C24H17NO2 (351.1259)


   

2-(3,4,5-Trimethoxybenzoyl)-4,4-diethyl-3,5-isoxazolidinedione

2-(3,4,5-Trimethoxybenzoyl)-4,4-diethyl-3,5-isoxazolidinedione

C17H21NO7 (351.1318)


   

1-(2-Methylpropyl)-1H-imidazo(4,5-c)(1,5)naphthyridin-4-amine monoethanesulfonate

1-(2-Methylpropyl)-1H-imidazo(4,5-c)(1,5)naphthyridin-4-amine monoethanesulfonate

C15H21N5O3S (351.1365)


   

L-Alanyl-L-phenylalanyl-L-aspartic acid

L-Alanyl-L-phenylalanyl-L-aspartic acid

C16H21N3O6 (351.143)


   

2-Oxocyclopiazonate

2-Oxocyclopiazonate

C20H19N2O4- (351.1345)


   

2-[[(2R)-2-amino-3-[(E)-N-hydroxy-C-(6-methylsulfanylhexyl)carbonimidoyl]sulfanylpropanoyl]amino]acetic acid

2-[[(2R)-2-amino-3-[(E)-N-hydroxy-C-(6-methylsulfanylhexyl)carbonimidoyl]sulfanylpropanoyl]amino]acetic acid

C13H25N3O4S2 (351.1286)


   

2-[[(4-Methyl-1-piperazinyl)-sulfanylidenemethyl]amino]benzene-1,4-dicarboxylic acid dimethyl ester

2-[[(4-Methyl-1-piperazinyl)-sulfanylidenemethyl]amino]benzene-1,4-dicarboxylic acid dimethyl ester

C16H21N3O4S (351.1253)


   

N-(4-ethoxyphenyl)-2-[4-[2-(methylthio)ethyl]-2,5-dioxo-1-imidazolidinyl]acetamide

N-(4-ethoxyphenyl)-2-[4-[2-(methylthio)ethyl]-2,5-dioxo-1-imidazolidinyl]acetamide

C16H21N3O4S (351.1253)


   

17beta-Hydroxyestra-1(10),2,4-trien-3-yl sulfate

17beta-Hydroxyestra-1(10),2,4-trien-3-yl sulfate

C18H23O5S- (351.1266)


   
   
   

N-(3,4-dimethylphenyl)-2-[[1-(phenylmethyl)-2-imidazolyl]thio]acetamide

N-(3,4-dimethylphenyl)-2-[[1-(phenylmethyl)-2-imidazolyl]thio]acetamide

C20H21N3OS (351.1405)


   

N-[5-(4-tert-butylphenyl)-1,3,4-thiadiazol-2-yl]-4-methylbenzamide

N-[5-(4-tert-butylphenyl)-1,3,4-thiadiazol-2-yl]-4-methylbenzamide

C20H21N3OS (351.1405)


   

17beta-Estradiol 17-sulfate

17beta-Estradiol 17-sulfate

C18H23O5S- (351.1266)


   

4-Hydroxy-3-methoxybenzaldehyde [5-(4-methoxyphenyl)-1,2,4-triazin-3-yl]hydrazone

4-Hydroxy-3-methoxybenzaldehyde [5-(4-methoxyphenyl)-1,2,4-triazin-3-yl]hydrazone

C18H17N5O3 (351.1331)


   

Phe-Ala-Asp

Phe-Ala-Asp

C16H21N3O6 (351.143)


A tripeptide composed of L-phenylalanine, L-alanine, and L-aspartic acid joined by peptide linkages.

   
   
   
   
   
   

3-[4-(3,4-dihydro-2H-1,5-benzodioxepin-7-ylsulfonyl)-1-piperazinyl]propanenitrile

3-[4-(3,4-dihydro-2H-1,5-benzodioxepin-7-ylsulfonyl)-1-piperazinyl]propanenitrile

C16H21N3O4S (351.1253)


   
   
   
   
   
   
   
   
   
   
   

2-(2,2-Dimethyl-4,6-dioxo-6-phenylhexyl)benzothiazole

2-(2,2-Dimethyl-4,6-dioxo-6-phenylhexyl)benzothiazole

C21H21NO2S (351.1293)


   

lomefloxacin

lomefloxacin

C17H19F2N3O3 (351.1394)


A fluoroquinolone antibiotic, used (generally as the hydrochloride salt) to treat bacterial infections including bronchitis and urinary tract infections. It is also used to prevent urinary tract infections prior to surgery. J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01M - Quinolone antibacterials > J01MA - Fluoroquinolones D000970 - Antineoplastic Agents > D059003 - Topoisomerase Inhibitors > D059005 - Topoisomerase II Inhibitors S - Sensory organs > S01 - Ophthalmologicals > S01A - Antiinfectives > S01AE - Fluoroquinolones D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D024841 - Fluoroquinolones C254 - Anti-Infective Agent > C258 - Antibiotic > C795 - Quinolone Antibiotic D004791 - Enzyme Inhibitors

   

17beta-estradiol 3-sulfate(1-)

17beta-estradiol 3-sulfate(1-)

C18H23O5S (351.1266)


A steroid sulfate oxoanion obtained by deprotonation of the sulfo group of 17beta-estradiol 3-sulfate; major species at pH 7.3.

   
   
   
   

methyl 2-{1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]indol-3-yl}acetate

methyl 2-{1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]indol-3-yl}acetate

C17H21NO7 (351.1318)


   

methyl 2-{1-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]indol-3-yl}acetate

methyl 2-{1-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]indol-3-yl}acetate

C17H21NO7 (351.1318)


   

{1-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]indol-3-yl}methyl acetate

{1-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]indol-3-yl}methyl acetate

C17H21NO7 (351.1318)


   

(2s,3z)-2-{[(2s)-2-amino-5-carbamimidamido-1-hydroxypentylidene]amino}-5-phosphonopent-3-enoic acid

(2s,3z)-2-{[(2s)-2-amino-5-carbamimidamido-1-hydroxypentylidene]amino}-5-phosphonopent-3-enoic acid

C11H22N5O6P (351.1308)


   

(3e)-2-[(2-amino-5-carbamimidamido-1-hydroxypentylidene)amino]-5-phosphonopent-3-enoic acid

(3e)-2-[(2-amino-5-carbamimidamido-1-hydroxypentylidene)amino]-5-phosphonopent-3-enoic acid

C11H22N5O6P (351.1308)